Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments.

Glioblastoma is one of the most common and detrimental forms of solid brain tumor, with over 10,000 new cases reported every year in the United States. Despite aggressive multimodal treatment approaches, the overall survival period is reported to be less than 15 months after diagnosis. A widely used approach for the treatment of glioblastoma is surgical removal of the tumor, followed by radiotherapy and chemotherapy. While there are several drugs available that are approved by the Food and Drug Administration (FDA), significant efforts have been made in recent years to develop new chemotherapeutic agents for the treatment of glioblastoma. This review describes the molecular targets and pathogenesis as well as the current progress in chemotherapeutic development and other novel therapies in the clinical setting for the treatment of glioblastoma.

Estimation of the proton affinity values of fifteen matrix-assisted laser desorption/ionization matrices under electrospray ionization conditions using the kinetic method.

The kinetic method, which is known to be simple, fast and precise, is used for the measurement of proton affinity values of fifteen selected matrix-assisted laser desorption/ionization matrices under electrospray ionization conditions. The stabilization of [M - H](-)/[M + Matrix - H](-) ions for beta-cyclodextrin in negative ion mode has been rationalized based on the proton affinity values of the matrices.